Search
Beam Therapeutics Inc
BEAMAdd to Watchlist
35.520USD
+1.200+3.50%
Market hours （ET）Quotes delayed by 15 min
3.65BMarket Cap
LossP/E TTM
More Details of Beam Therapeutics Inc Company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Beam Therapeutics Inc Info
Ticker SymbolBEAM
Company nameBeam Therapeutics Inc
IPO dateFeb 06, 2020
CEOEvans (John M)
Number of employees483
Security typeOrdinary Share
Fiscal year-endFeb 06
Address238 Main Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone18573278775
Websitehttps://beamtx.com/
Ticker SymbolBEAM
IPO dateFeb 06, 2020
CEOEvans (John M)
Company Executives of Beam Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
178.91K
+19.85%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
26.79K
-25.01%
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Independent Director
Independent Director
--
--
Ms. Kathleen E. Walsh
Ms. Kathleen E. Walsh
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
178.91K
+19.85%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
26.79K
-25.01%
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Beam Therapeutics Inc?
The top five shareholders of Beam Therapeutics Inc are: Dr. Giuseppe Ciaramella, Ph.D.
How many institutions hold shares of Beam Therapeutics Inc (BEAM)?
As of 2026Q1, 560 institutions hold shares of Beam Therapeutics Inc, with a combined market value of approximately 106.16M, accounting for 103.20% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -6468210.00.